Ginkgo Bioworks Holdings, Inc.

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:02 11/05/2024 am IST			5-day change	1st Jan Change
0.7609 ^USD	-17.29%		-20.32%	-54.98%

10/05	William Blair Downgrades Ginkgo Bioworks Holdings to Underperform From Market Perform	MT
10/05	Ginkgo Bioworks Holdings Q1 Loss Narrows, Revenue Drops; 2024 Revenue Outlook Slashed; Cost Cuts Planned	MT

Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics.

April 02, 2024

Ginkgo Bioworks (NYSE: DNA) acquired cell therapy platform assets of Modulus Therapeutics on April 2, 2024.

Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics on April 2, 2024.

Latest news about Ginkgo Bioworks Holdings, Inc.

William Blair Downgrades Ginkgo Bioworks Holdings to Underperform From Market Perform	10/05	MT
Ginkgo Bioworks Holdings Q1 Loss Narrows, Revenue Drops; 2024 Revenue Outlook Slashed; Cost Cuts Planned	10/05	MT
Transcript : Ginkgo Bioworks Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q1 Revenue $38M, vs. Street Est of $46M	10/05	MT
Ginkgo Bioworks, GreenLab Launch Partnership to Produce Sugar Substitute Brazzein	07/05	MT
GreenLab and Ginkgo Bioworks Announce New Partnership	07/05	CI
Il Granaio delle Idee and Ginkgo Bioworks Announces Strategic Collaboration to Optimize Sourdough Strains for Bakery Products	16/04	CI
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024	11/04
Ginkgo Bioworks Acquires AgBiome's Platform Assets	11/04	MT
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk	10/04	MT
Ginkgo Bioworks Partners With IdeeLab Biotechnology in Brazil	08/04	MT
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service	08/04	CI
Ginkgo Bioworks, Prozomix Collaborate on Enzyme Development	03/04	MT
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing	03/04	CI
Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics.	02/04	CI
Ginkgo Bioworks Awarded $6 Million DARPA Contract to Work on Cold-Weather Applications for Military and Commercial Use	28/03	MT
Ginkgo Bioworks Wins DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments	28/03	CI
Ginkgo Bioworks, AQUA Cultured Foods to Support Fish-Free Seafood Production	27/03	MT
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production	27/03	CI
Ginkgo Bioworks, Imagindairy to Develop Animal-Free Dairy Proteins	26/03	MT
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins	26/03	CI
Ginkgo Bioworks Collaborating With Dutch Biotech ProteoNic to Extend Proteins Production, Genetic Therapies	13/03	MT
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	06/03
TD Cowen Cuts Price Target on Ginkgo Bioworks to $3 From $7, Maintains Outperform Rating	01/03	MT
Transcript : Ginkgo Bioworks Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024	01/03

Chart Ginkgo Bioworks Holdings, Inc.

Duration

Period

More charts

Company Profile

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Sector

Biotechnology & Medical Research

Calendar

08:15pm - American Society of Gene & Cell Therapy Meeting - Abstract No: 410

More about the company

Income Statement Evolution

More financial data

Ratings for Ginkgo Bioworks Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.7609 USD

Average target price

1.88 USD

Spread / Average Target

+147.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GINKGO BIOWORKS HOLDINGS, INC.	-54.98%	1.68B
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research